Skip to main content

Table 1 Chemotherapeutics and the incidence or prevalence of reported neuropathies

From: Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Chemotherapy Class Approximate incidence/prevalence of CIPN (%) References
Oxaliplatin Platinum-based chemotherapeutics Acute: 85–96; chronic wide range: 40–93 [3]
Cisplatin 12–85
Paclitaxel Taxanes 61–92 [2, 4]
Bortezomib Proteasome inhibitor 47–80
Vincristine Vinca alkaloids 14–70 [5]
Thalidomide Immunomodulatory drugs 21–50 [6]
  1. Data are mainly from randomized controlled trials or prospective cohort studies
  2. CIPN Chemotherapy-induced peripheral neuropathy